Background and purpose: NCAPD2 is a protein-coding gene that plays a key role in cell proliferation

such as mitosis process. This study aimed to investigate the expression level and clinical value of NCAPD2 in glioma. Methods: The expression of NCAPD2 mRNA in various malignant tumor tissues was analyzed by GEPIA database. The expression level of NCAPD2 mRNA in glioma was analyzed by Ualcan

UCSC Xena and TIMER2.0 database. Immunohistochemical S-P method was used to detect and analyze the expression of NCAPD2 protein in normal brain tissue and glioma tissue

as well as the relationship between the overexpression of NCAPD2 protein and the clinicopathological features of glioma. The expression level of NCAPD2 in glioma cells was verified by Western blot. LinkedOmics database was used to explore genes co-expressed with NCAPD2. Metascape database and GoPlot database were used for enrichment analysis. Results: Database analysis showed that the expression of NCAPD2 was higher in various malignant tissues than in normal tissues (P ＜ 0.05)

and the expression level of NCAPD2 was higher in isocitrate dehydrogenase 1 (IDH1) mutant-type glioma than in IDH1 wild-type glioma (P ＜ 0.05). Immunohistochemical results showed that NCAPD2 protein was mainly expressed in the nucleus and cytoplasm

and the positive expression rate and strong positive expression rate of NCAPD2 protein in glioma tissues were significantly higher than those in normal brain tissues (P ＜ 0.01). However

NCAPD2 protein was positively correlated with clinical classification of glioma patients (P ＜ 0.05). Western blot assay showed that the expression of NCAPD2 protein in glioma cells was significantly higher than in glial cells (P ＜ 0.05). GO enrichment analysis showed that NCAPD2 gene was mainly related to cell cycle progression (P ＜ 0.01). Conclusion: The overexpression of NCAPD2 in glioma is closely related to clinical grade and cell cycle progression

which indicates that NCAPD2 plays an important role in the occurrence and development of glioma.